BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 30 May 2018 Planned number of patients changed from 850 to 1430.
- 27 Mar 2018 Planned primary completion date changed from 28 May 2018 to 3 Aug 2018.